AU2020338688A1 - Compstatin analogues and their medical uses - Google Patents

Compstatin analogues and their medical uses Download PDF

Info

Publication number
AU2020338688A1
AU2020338688A1 AU2020338688A AU2020338688A AU2020338688A1 AU 2020338688 A1 AU2020338688 A1 AU 2020338688A1 AU 2020338688 A AU2020338688 A AU 2020338688A AU 2020338688 A AU2020338688 A AU 2020338688A AU 2020338688 A1 AU2020338688 A1 AU 2020338688A1
Authority
AU
Australia
Prior art keywords
analogue
compound
sar
trp
peg3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020338688A
Other languages
English (en)
Inventor
Henrik Fischer MUNCH
Anne Pernille Tofteng SHELTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zp Spv 3 K/s
Original Assignee
Zp Spv 3 K/s
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/s filed Critical Zp Spv 3 K/s
Publication of AU2020338688A1 publication Critical patent/AU2020338688A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2020338688A 2019-08-27 2020-08-26 Compstatin analogues and their medical uses Pending AU2020338688A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19193925.5 2019-08-27
EP19193925 2019-08-27
EP20172189 2020-04-29
EP20172189.1 2020-04-29
PCT/EP2020/073905 WO2021037942A1 (en) 2019-08-27 2020-08-26 Compstatin analogues and their medical uses

Publications (1)

Publication Number Publication Date
AU2020338688A1 true AU2020338688A1 (en) 2022-03-24

Family

ID=72178552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020338688A Pending AU2020338688A1 (en) 2019-08-27 2020-08-26 Compstatin analogues and their medical uses

Country Status (13)

Country Link
US (1) US20220306695A1 (ja)
EP (2) EP4272751A3 (ja)
JP (1) JP2022545916A (ja)
KR (1) KR20220066287A (ja)
CN (1) CN114630836A (ja)
AU (1) AU2020338688A1 (ja)
BR (1) BR112022003760A2 (ja)
CA (1) CA3148536A1 (ja)
CO (1) CO2022003556A2 (ja)
IL (1) IL290858A (ja)
MX (1) MX2022002433A (ja)
TW (1) TW202128731A (ja)
WO (1) WO2021037942A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3759120A1 (en) * 2018-02-27 2021-01-06 Zp Spv 3 K/S Compstatin analogues and their medical uses
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023048151A1 (ja) * 2021-09-22 2023-03-30 塩野義製薬株式会社 ウイルス増殖阻害活性を有する環状ペプチド

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2248772C (en) 1996-03-13 2007-06-12 John D. Lambris Novel peptides which inhibit complement activation
PT944648E (pt) 1996-08-30 2007-06-26 Novo Nordisk As Derivados do glp-1.
ES2239364T3 (es) 1996-09-09 2005-09-16 Zealand Pharma A/S Sintesis de peptidos en fase solida.
AU4648197A (en) * 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1163211B1 (en) 1999-03-17 2008-09-24 Novo Nordisk A/S Method for acylating peptides and proteins
SI1549333T1 (sl) 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
EP1951279B1 (en) 2005-10-08 2017-04-12 Apellis Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
PL1960422T3 (pl) 2005-11-28 2012-11-30 Univ Pennsylvania Silne analogi kampstatyny
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
AU2009298684B2 (en) * 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
US20140113874A1 (en) * 2010-09-23 2014-04-24 The Trustees Of The University Of Pennsylvania Modified Compstatin With Improved Stability And Binding Properties
DK2753636T3 (da) 2011-09-07 2020-02-03 Univ Pennsylvania Compstatinanaloger med forbedret farmakokinetiske egenskaber
US9512180B2 (en) * 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US20180057538A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Potent and highly soluble pegylated compstatin peptides
EP3759120A1 (en) * 2018-02-27 2021-01-06 Zp Spv 3 K/S Compstatin analogues and their medical uses

Also Published As

Publication number Publication date
CA3148536A1 (en) 2021-03-04
MX2022002433A (es) 2022-05-19
IL290858A (en) 2022-04-01
KR20220066287A (ko) 2022-05-24
EP4272751A3 (en) 2024-02-14
CO2022003556A2 (es) 2022-05-20
EP4021921A1 (en) 2022-07-06
US20220306695A1 (en) 2022-09-29
JP2022545916A (ja) 2022-11-01
CN114630836A (zh) 2022-06-14
WO2021037942A1 (en) 2021-03-04
TW202128731A (zh) 2021-08-01
EP4272751A2 (en) 2023-11-08
BR112022003760A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
JP6676589B2 (ja) 薬物動態特性の改善されたコンプスタチンアナログ
US11965039B2 (en) Compstatin analogues and their medical uses
JP2020128443A (ja) インターロイキン２３受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用
EP4272751A2 (en) Compstatin analogues and their medical uses
US10213476B2 (en) Compstatin analogs with improved potency and pharmacokinetic properties
US20230287051A1 (en) Inhibitors of complement factor c3 and their medical uses
US20190092816A9 (en) Stapled peptides and uses thereof
JP7195281B2 (ja) ペプチドｐａｃ１アンタゴニスト
WO2024029242A1 (ja) 新規ｌｒｐ１結合ペプチド
US11975040B2 (en) Plexin binding regulator
CN116457000A (zh) 缀合的铁调素模拟物
Bowerman et al. Aromatic Versus Hydrophobic Contributions to Amyloid Peptide Self-Assembly